Our current policy for transfusing our sickle patients is to honor their Rh and Kell phenotypes until they form a clinically significant antibody. At that point we will honor their full phenotype as they are considered a responder. But if they form a clinically insignificant antibody, we continue to honor only the Rh and Kell phenotype. Are only patients who form clinically significant antibodies considered responders? This has become a topic of conversation at our hospital and no one is sure what the correct answer is. If any one has any info that would shed some light is would be greatly appreciated!! Thanks!! (Also, if you have any articles siting this it would be even better!!)